Fig. 1a.

Time series plot of percent of patients receiving NAC by year using ARIMA models. There was a significant increase in use of NAC from a mean of 7.7% before the MDBCC to 47.6% in the 2012 academic year. MDBCC: multidisciplinary bladder cancer clinic; NAC: neoadjuvant chemotherapy.